Hypothesis

Intermittent fasting combined with NMN supplementation increases SIRT1 enzymatic activity in human skeletal muscle more than either intervention alone.

Rationale

NMN and NR reliably double circulating NAD+ levels after two weeks[1], yet no study has shown that this rise translates into SIRT1 activation in human tissues[1]. Fasting elevates NAMPT expression, boosting the NAD+ salvage pathway and promoting fat browning and glucose homeostasis in liver[3]. In mice, time‑restricted feeding plus NMN raises muscle NAD+/NADH ratios beyond each treatment singly, improving mitochondrial function and exercise capacity[2]. These data suggest that fasting may shift NAD+ toward nuclear compartments where SIRT1 resides, while NMN supplies the precursor. Together they could overcome the NAD+‑availability bottleneck that limits SIRT1 firing.

Predictions

1. Participants receiving NMN plus intermittent fasting will exhibit a greater increase in muscle NAD+/NADH ratio than those receiving NMN alone or fasting alone.
2. Elevated NAD+/NADH will correlate with higher SIRT1 activity, measured by decreased acetylation of known substrates such as PGC‑1α and FOXO3a in muscle biopsies.
3. Functional readouts—mitochondrial respiration (via high‑resolution respirometry) and insulin‑stimulated glucose uptake—will improve only in the combined group.

Experimental design

A randomized, crossover trial with three 4‑week arms separated by 4‑week washouts: (A) NMN 250 mg daily, (B) intermittent fasting (16:8 schedule), (C) NMN + intermittent fasting. Primary outcomes: muscle NAD+/NADH ratio (LC‑MS), SIRT1 activity (fluorometric deacetylase assay), and acetylation status of PGC‑1α/FOXO3a (Western blot). Secondary outcomes: VO2max, resting metabolic rate, and fasting glucose.

Potential outcomes

If the hypothesis holds, the combined arm will show a statistically significant rise in SIRT1 activity and downstream metabolic benefits compared with monotherapies. A null result—no difference in SIRT1 acetylation despite NAD+ elevation—would falsify the premise that fasting redirects NMN‑derived NAD+ to nuclear SIRT1, indicating that additional regulatory layers (e.g., NAD+‑binding proteins, compartmental transporters) govern sirtuin activation in humans.

Novel mechanistic insight

We propose that fasting‑induced NAMPT upregulation preferentially enriches the nucleocytosolic NAD+ pool, whereas NMN supplementation primarily elevates cytosolic NAD+. SIRT1 resides in the nucleus; thus, only when both interventions coincide does nuclear NAD+ reach the threshold needed for efficient deacetylation. This compartment‑specific synergy explains why NAD+ elevation alone fails to activate SIRT1 and offers a testable, falsifiable mechanism linking NAD+ precursors, fasting rhythms, and sirtuin signaling.